Swapan K Chowdhury
Overview
Explore the profile of Swapan K Chowdhury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Shah A, Kato S, Griffin R, Zhang S, Pusalkar S, et al.
Drug Metab Dispos
. 2024 Jul;
52(10):1115-1123.
PMID: 39038951
Mobocertinib (formerly known as TAK-788) is a targeted covalent tyrosine kinase inhibitor of epidermal growth factor receptor with exon 20 insertion mutations. This article describes the metabolism and excretion of...
2.
Yin W, Ballard T, Zhu S, Hsiao S, Chen H, Li Y, et al.
Br J Clin Pharmacol
. 2023 Sep;
90(2):516-527.
PMID: 37771051
Aims: Our aim was to determine the absolute bioavailability, mass balance, metabolism and excretion of soticlestat (TAK-935). Methods: An open-label, two-period, single-site, phase 1 study was conducted in six healthy...
3.
Sandoval P, Chuang B, Fallon J, Smith P, Chowdhury S, Griffin R, et al.
AAPS J
. 2022 Sep;
24(6):99.
PMID: 36123502
The liver is central to the elimination of many drugs from the body involving multiple processes and understanding of these processes is important to quantitively assess hepatic clearance of drugs....
4.
Sandoval P, Chuang B, Cohen L, Yoneyama T, Pusalkar S, Yucha R, et al.
Drug Metab Dispos
. 2022 May;
50(7):980-988.
PMID: 35545257
Quantitative assessment of hepatic clearance (CL) of drugs is critical to accurately predict human dose and drug-drug interaction (DDI) liabilities. This is challenging for drugs that involve complex transporter-enzyme interplay....
5.
Bolleddula J, Chen H, Cohen L, Zhou X, Pusalkar S, Berger A, et al.
Drug Metab Dispos
. 2022 May;
50(7):989-997.
PMID: 35504658
Metabolism and disposition of pevonedistat, an investigational, first-in-class inhibitor of the NEDD8-activating enzyme (NAE), were characterized in patients with advanced solid tumors after intravenous infusion of [C]pevonedistat at 25 mg/m...
6.
Guo Y, Shah A, Oh E, Chowdhury S, Zhu X
Drug Metab Dispos
. 2022 Mar;
50(5):716-724.
PMID: 35241454
Glucuronidation is the most common phase II metabolic pathway to eliminate small molecule drugs from the body. However, determination of glucuronide structure is quite challenging by mass spectrometry due to...
7.
Pusalkar S, Chowdhury S, Czerniak R, Zhu X, Li Y, Balani S, et al.
Eur J Drug Metab Pharmacokinet
. 2022 Feb;
47(3):371-386.
PMID: 35157234
Background And Objective: Felcisetrag (previously TAK-954 or TD-8954) is a highly selective and potent 5-HT receptor agonist in clinical development for prophylaxis and treatment of postoperative gastrointestinal dysfunction (POGD). The...
8.
Pharmacokinetics and Catabolism of [H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate
Bolleddula J, Shah A, Shadid M, Kamali A, Smith M, Chowdhury S
Drug Metab Dispos
. 2020 Aug;
48(11):1239-1245.
PMID: 32843329
TAK-164 is an antibody-drug conjugate (ADC) comprising human anti-guanylyl cyclase C (GCC) monoclonal antibody conjugated to indolinobenzodiazepine DNA alkylator IGN-P1 through a cleavable alanine-alanine dipeptide linker. TAK-164 is currently being...
9.
Pusalkar S, Zhou X, Li Y, Cohen L, Yang J, Balani S, et al.
Drug Metab Dispos
. 2020 Jan;
48(3):217-229.
PMID: 31911485
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted...
10.
Zhou X, Pusalkar S, Chowdhury S, Searle S, Li Y, Ullmann C, et al.
Invest New Drugs
. 2018 Nov;
37(4):666-673.
PMID: 30397836
Aims This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics and safety of the investigational aurora A kinase inhibitor, alisertib, in three patients with advanced malignancies. Methods Part...